Naslov
Plerixafor for Autologous Peripheral Blood Stem Cell Mobilization in Patients Previously Treated with Fludarabine or Lenalidomide

Autori
Malard, F. ; Kröger, N. ; Gabriel, I.H. ; Hübel, K. ; Apperley, J.F. ; Basak, G.W. ; Douglas, K.W. ; Geraldes, C. ; Jakšić, Ozren ; Koristek, Z. ; Lanza, F. ; Lemoli, R. ; Mikala, G. ; Selleslag, D. ; Worel, N. ; Mohty, M. ; Duarte, R.F.

Izvornik
Biology of blood and marrow transplantation (1083-8791) 18 (2012), 2; 314-317

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
autologous stem cell mobilization; plerixafor; salvage mobilization; fludarabine

Sažetak
Fludarabine and lenalidomide are essential drugs in the front line treatment of non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM), respectively. Data suggests that fludarabine and lenalidomide therapy may have a deleterious effect on stem cell mobilization. In the European compassionate use program, 48 patients (median age 57 years), previously treated with fludarabine (median 5 cycles ; range: 1-7 cycles) were given plerixafor plus granulocyte colony stimulating factor (G-CSF) for remobilization following a primary mobilization attempt. The overall median number of CD34(+) cells collected was 2.3 × 10(6)/kg (range: 0.3-13.4). The minimum required number of CD34(+) cells (≥2.0 × 10(6)/kg) was collected from 58% of patients in a median of 2 days. Thirty-five patients (median age = 57 years), previously treated with lenalidomide (median 5 cycles ; range: 1-10 cycles) were given plerixafor plus G-CSF for remobilization. The overall median number of CD34(+) cells collected was 3.4 × 10(6)/kg (range: 1.1-14.8). The minimum required number of CD34(+) cells (≥2.0 × 10(6) per kg) was collected from 69% of patients in a median of 2 days. In conclusion, salvage mobilization with plerixafor plus G-CSF is successful in the majority of patients with MM previously treated with lenalidomide. In fludarabine-exposed patients, only 58% of patients will achieve successful salvage mobilization with plerixafor plus G-CSF, suggesting the need for novel mobilization regimens algorithms in this subgroup of patients.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA